Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anchen Pharmaceuticals Inc.

Division of Endo International PLC
www.anchen.com

Latest From Anchen Pharmaceuticals Inc.

Namenda XR Generics Coming Soon? US Court Rulings Clear Path For Multiple Launches

Seven companies hold final ANDA approval for Alzheimer's drug, but Allergan still has chance to block them as it seeks rehearing of appeals court's patent decision. Meanwhile, Amneal might block other generics if it can get an appeals court to grant it the 180-day marketing exclusivity for memantine extended-release it says that FDA unfairly denied it.

Generic Drugs Legal Issues

Namenda XR Generics Coming Soon? US Court Rulings Clear Path For Multiple Launches

Seven companies hold final ANDA approval for Alzheimer's drug, but Allergan still has chance to block them as it seeks rehearing of appeals court's patent decision. Meanwhile, Amneal might block other generics if it can get an appeals court to grant it the 180-day marketing exclusivity for memantine extended-release it says that FDA unfairly denied it.

Generic Drugs Legal Issues

Par Enters Generic Injectable Market Via JHP Buy

The generics maker is expanding its portfolio of reformulations through the acquisition of privately-held JHP in a deal worth $490 million, expected to close in short order.

BioPharmaceutical North America

Sucampo Puts 40 Reps Behind Rescula Launch As it Seeks Revitalization

Tiny Sucampo is betting that its new drug Rescula can make inroads in a heavily generic market because of its clean safety profile and efficacy, but at $99 per 30-day supply WAC, it faces significant headwinds.

BioPharmaceutical Launches
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
    • Generic Drugs
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Endo International PLC
  • Senior Management
  • Chih-Ming Chen, PhD, CEO & Chrmn.
  • Contact Info
  • Anchen Pharmaceuticals Inc.
    Phone: (949) 639-8100
    9601 Jeronimo
    Irvine, CA 92618
    USA
UsernamePublicRestriction

Register